Latest News

Experts shared their clinical perspectives on trending topics in the treatment and management of movement disorders at the 2025 International Congress of Parkinson’s Disease and Movement Disorders (MDS).

Clinical trial data presented at the 2025 International Congress of Parkinson’s Disease and Movement Disorders showed that pimavanserin had positive efficacy in patients showing Parkinson Disease psychosis symptoms who were treated earlier.

New findings reveal early treatment with Trappsol Cyclo shows promise for young patients with Niemann-Pick disease type C1, enhancing safety and efficacy.

In honor of International Stuttering Awareness Day, the founder of the Stuttering Treatment and Research Society discussed understanding the diagnosis of stuttering and the importance of early intervention for patients.

David Stamler, MD, chief executive officer at Alterity Therapeutics, gave clinical perspectives on ATH434, an emerging agent showing promise in phase 2 studies of multiple system atrophy.

A recent review of studies over the past decade, presented at CNS 2025, suggests that the ketogenic diet can significantly reduce seizure frequency in children with drug-resistant epilepsy.

A new study reported that children and adolescents with Tourette syndrome on dopamine D2 receptor antagonists had higher rates of psychiatric and metabolic adverse events than those unexposed.

Beth McQuiston, MD, neurologist and medical director in Abbott’s diagnostics business, discussed the clinical value of Abbott’s FDA-cleared i-STAT TBI test as it was named to TIME’S 2025 Best Inventions List.

Leigh Charvet, PhD, professor of neurology at NYU Grossman School of Medicine, provided clinical insights to her team’s pilot study using at-home brain stimulation to reduce cannabis use in women with multiple sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

Researchers recently received a $2.8 million 3-year grant to develop next-generation implantable responsive neurostimulation devices for patients with epilepsy.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on deep brain stimulation for Parkinson disease.

An interim analysis from TEMPO-4, presented as a late-breaker at MDS 2025, showed that tavapadon showed sustained long-term safety in Parkinson disease.